Pharma & Healthcare

Global VEGF Inhibitors Market Outlook, In‑Depth Analysis & Forecast to 2031

Report Includes:
This definitive report equips CEOs, marketing directors, and investors with a 360° view of the global VEGF Inhibitors market, seamlessly integrating production and sales performance across the value chain. It analyzes historical sales volume and revenue sales data (2020–2024) and delivers forecasts through 2031, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies volume and value, growth rates, technical innovations, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.
Granular regional insights cover five major markets—North America, Europe, APAC, South America, and MEA—with in‑depth analysis of 20+ countries. Each region’s dominant products, competitive landscape, and downstream demand trends are clearly detailed.
Critical competitive intelligence profiles manufacturers—sales volume, revenue, margins, pricing strategies, and major customers—and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise supply‑chain overview maps upstream suppliers, manufacturing technologies, cost structures, and distribution dynamics to identify strategic gaps and unmet demand.
Market Segmentation
By Company
Roche
Novartis
Coherus BioSciences
Bayer
Amneal Pharmaceuticals
Sanofi
Samsung Bioepis
Eli Lilly
Pfizer
Celltrion Healthcare
Amgen
Chengdu Kanghong Pharmaceutical
Segment by Type
Monoclonal Antibodies
Fusion Proteins
Segment by Application
Degenerative Eye Diseases
Cancer
Other
Sales by Region
North America
U.S.
Canada
Mexico
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia (Indonesia, Vietnam, Thailand)
India
Europe
Germany
France
U.K.
Italy
Russia
Central South America
Brazil
Argentina
Middle East, Africa
Turkey
Egypt
GCC Countries
South Africa
Chapter Outline
Chapter 1: Defines the VEGF Inhibitors study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential.
Chapter 2: Offers current market state, projects global revenue and sales to 2031, pinpointing high consumption regions and emerging market catalysts
Chapter 3: Dissects the manufacturer landscape—ranks by volume and revenue, analyzes profitability and pricing, maps production bases, details manufacturer performance by product type and evaluates concentration alongside M&A moves.
Chapter 4: Unlocks high margin product segments—compares sales, revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
Chapter 5: Targets downstream market opportunities—evaluates sales, revenue, and pricing by Application, identifies emerging use cases, and profiles leading customers by region and by Application.
Chapter 6: North America—breaks down sales and revenue by Type, by Application and country, profiles key manufacturers and assesses growth drivers and barriers.
Chapter 7: Europe—analyses regional sales, revenue and market by Type, by Application and manufacturers, flagging drivers and barriers.
Chapter 8: Asia Pacific—quantifies sales and revenue by Type, by Application, and region/country, profiles top manufacturers, and uncovers high potential expansion areas.
Chapter 9: Central & South America—measures sales and revenue by Type, by Application, and country, profiles top manufacturers, and identifies investment opportunities and challenges.
Chapter 10: Middle East and Africa—evaluates sales and revenue by Type, by Application, and country, profiles key manufacturers, and outlines investment prospects and market hurdles
Chapter 11: Profiles manufacturers in depth—details product specs, sales, revenue, margins; Top manufactures 2024 sales breakdowns by Product type, by Application, by sales region SWOT analysis, and recent strategic developments.
Chapter 12: Supply chain—analyses upstream raw materials and suppliers, manufacturing footprint, regional production and cost, regulatory and technology, plus downstream channels and distributor roles.
Chapter 13: Market dynamics—explores drivers, restraints, regulatory impacts, and risk mitigation strategies.
Chapter 15: Actionable conclusions and strategic recommendations.
Why This Report:
Beyond standard market data, this analysis provides a clear profitability roadmap—empowering you to:
Allocate capital strategically to high growth regions (Chapters 6–10) and margin rich segments (Chapter 5).
Negotiate from strength with suppliers (Chapter 12) and customers (Chapter5) using cost and demand intelligence.
Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
Secure your supply chain against disruptions through upstream and downstream visibility (Chapters 12 and 13).
Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.
1 Study Coverage
1.1 Introduction to VEGF Inhibitors: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global VEGF Inhibitors Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 Monoclonal Antibodies
1.2.3 Fusion Proteins
1.3 Market Segmentation by Application
1.3.1 Global VEGF Inhibitors Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Degenerative Eye Diseases
1.3.3 Cancer
1.3.4 Other
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global VEGF Inhibitors Revenue Estimates and Forecasts 2020-2031
2.2 Global VEGF Inhibitors Revenue by Region
2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031
2.2.2 Historical and Forecasted Revenue by Region (2020--2031)
2.2.3 Global Revenue Market Share by Region (2020-2031)
2.3 Global VEGF Inhibitors Sales Estimates and Forecasts 2020-2031
2.4 Global VEGF Inhibitors Sales by Region
2.4.1 Sales Comparison: 2020 VS 2024 VS 2031
2.4.2 Historical and Forecasted Sales by Region (2020-2031)
2.4.3 Emerging Market Focus: Growth Drivers & Investment Trends
2.4.4 Global Sales Market Share by Region (2020-2031)
3 Competition by Manufacturers
3.1 Global VEGF Inhibitors Sales by Manufacturers
3.1.1 Global Sales Volume by Manufacturers (2020-2025)
3.1.2 Global Top 5 and Top 10 Manufacturers’Market Share by Sales Volume (2024)
3.2 Global VEGF Inhibitors Manufacturer Revenue Rankings and Tiers
3.2.1 Global Revenue (Value) by Manufacturers (2020-2025)
3.2.2 Global Key Manufacturer Revenue Ranking (2023 vs. 2024)
3.2.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.3 Manufacturer Profitability Profiles and Pricing Strategies
3.3.1 Gross Margin by Top Manufacturer (2020 VS 2024)
3.3.2 Manufacturer-Level Price Trends (2020-2025)
3.4 Key Manufacturers Manufacturing Base and Headquarters
3.5 Main Product Type Market Size by Manufacturers
3.5.1 Monoclonal Antibodies Market Size by Manufacturers
3.5.2 Fusion Proteins Market Size by Manufacturers
3.6 Global VEGF Inhibitors Market Concentration and Dynamics
3.6.1 Global Market Concentration (CR5 and HHI)
3.6.2 Entrant/Exit Impact Analysis
3.6.3 Strategic Moves: M&A, Capacity Expansion, R&D Investment
4 Global Product Segmentation Analysis
4.1 Global VEGF Inhibitors Sales Performance by Type
4.1.1 Global Historical and Forecasted Sales by Type (2020-2031)
4.1.2 Global Sales Market Share by Type (2020-2031)
4.2 Global VEGF Inhibitors Revenue Trends by Type
4.2.1 Global Historical and Forecasted Revenue by Type (2020-2031)
4.2.2 Global Revenue Market Share by Type (2020-2031)
4.3 Global Average Selling Price (ASP) Trends by Type (2020-2031)
4.4 Product Technology Differentiation
4.5 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.5.1 High-Growth Niches and Adoption Drivers
4.5.2 Profitability Hotspots and Cost Drivers
4.5.3 Substitution Threats
5 Global Downstream Application Analysis
5.1 Global VEGF Inhibitors Sales by Application
5.1.1 Global Historical and Forecasted Sales by Application (2020-2031)
5.1.2 Global Sales Market Share by Application (2020-2031)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Global VEGF Inhibitors Revenue by Application
5.2.1 Global Historical and Forecasted Revenue by Application (2020-2031)
5.2.2 Revenue Market Share by Application (2020-2031)
5.3 Global Pricing Dynamics by Application (2020-2031)
5.4 Downstream Customer Analysis
5.4.1 Top Customers by Region
5.4.2 Top Customers by Application
6 North America
6.1 North America Sales Volume and Revenue (2020-2031)
6.2 North America Key Manufacturers Sales Revenue in 2024
6.3 North America VEGF Inhibitors Sales and Revenue by Type (2020-2031)
6.4 North America VEGF Inhibitors Sales and Revenue by Application (2020-2031)
6.5 North America Growth Accelerators and Market Barriers
6.6 North America VEGF Inhibitors Market Size by Country
6.6.1 North America Revenue by Country
6.6.2 North America Sales Trends by Country
6.6.3 US
6.6.4 Canada
6.6.5 Mexico
7 Europe
7.1 Europe Sales Volume and Revenue (2020-2031)
7.2 Europe Key Manufacturers Sales Revenue in 2024
7.3 Europe VEGF Inhibitors Sales and Revenue by Type (2020-2031)
7.4 Europe VEGF Inhibitors Sales and Revenue by Application (2020-2031)
7.5 Europe Growth Accelerators and Market Barriers
7.6 Europe VEGF Inhibitors Market Size by Country
7.6.1 Europe Revenue by Country
7.6.2 Europe Sales Trends by Country
7.6.3 Germany
7.6.4 France
7.6.5 U.K.
7.6.6 Italy
7.6.7 Russia
8 Asia-Pacific
8.1 Asia-Pacific Sales Volume and Revenue (2020-2031)
8.2 Asia-Pacific Key Manufacturers Sales Revenue in 2024
8.3 Asia-Pacific VEGF Inhibitors Sales and Revenue by Type (2020-2031)
8.4 Asia-Pacific VEGF Inhibitors Sales and Revenue by Application (2020-2031)
8.5 Asia-Pacific VEGF Inhibitors Market Size by Region
8.5.1 Asia-Pacific Revenue by Region
8.5.2 Asia-Pacific Sales Trends by Region
8.6 Asia-Pacific Growth Accelerators and Market Barriers
8.7 Southeast Asia
8.7.1 Southeast Asia Revenue by Country (2020 VS 2024 VS 2031)
8.7.2 Key Country Analysis: Indonesia, Vietnam, Thailand, Malaysia, Philippines
8.8 China
8.9 Japan
8.10 South Korea
8.11 China Taiwan
8.12 India
9 Central and South America
9.1 Central and South America Sales Volume and Revenue (2020-2031)
9.2 Central and South America Key Manufacturers Sales Revenue in 2024
9.3 Central and South America VEGF Inhibitors Sales and Revenue by Type (2020-2031)
9.4 Central and South America VEGF Inhibitors Sales and Revenue by Application (2020-2031)
9.5 Central and South America Investment Opportunities and Key Challenges
9.6 Central and South America VEGF Inhibitors Market Size by Country
9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)
9.6.2 Brazil
9.6.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Sales Volume and Revenue (2020-2031)
10.2 Middle East and Africa Key Manufacturers Sales Revenue in 2024
10.3 Middle East and Africa VEGF Inhibitors Sales and Revenue by Type (2020-2031)
10.4 Middle East and Africa VEGF Inhibitors Sales and Revenue by Application (2020-2031)
10.5 Middle East and Africa Investment Opportunities and Key Challenges
10.6 Middle East and Africa VEGF Inhibitors Market Size by Country
10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)
10.6.2 GCC Countries
10.6.3 Turkey
10.6.4 Egypt
10.6.5 South Africa
11 Corporate Profile
11.1 Roche
11.1.1 Roche Corporation Information
11.1.2 Roche Business Overview
11.1.3 Roche VEGF Inhibitors Product Models, Descriptions and Specifications
11.1.4 Roche VEGF Inhibitors Sales, Price, Revenue and Gross Margin (2020-2025)
11.1.5 Roche VEGF Inhibitors Sales by Product in 2024
11.1.6 Roche VEGF Inhibitors Sales by Application in 2024
11.1.7 Roche VEGF Inhibitors Sales by Geographic Area in 2024
11.1.8 Roche VEGF Inhibitors SWOT Analysis
11.1.9 Roche Recent Developments
11.2 Novartis
11.2.1 Novartis Corporation Information
11.2.2 Novartis Business Overview
11.2.3 Novartis VEGF Inhibitors Product Models, Descriptions and Specifications
11.2.4 Novartis VEGF Inhibitors Sales, Price, Revenue and Gross Margin (2020-2025)
11.2.5 Novartis VEGF Inhibitors Sales by Product in 2024
11.2.6 Novartis VEGF Inhibitors Sales by Application in 2024
11.2.7 Novartis VEGF Inhibitors Sales by Geographic Area in 2024
11.2.8 Novartis VEGF Inhibitors SWOT Analysis
11.2.9 Novartis Recent Developments
11.3 Coherus BioSciences
11.3.1 Coherus BioSciences Corporation Information
11.3.2 Coherus BioSciences Business Overview
11.3.3 Coherus BioSciences VEGF Inhibitors Product Models, Descriptions and Specifications
11.3.4 Coherus BioSciences VEGF Inhibitors Sales, Price, Revenue and Gross Margin (2020-2025)
11.3.5 Coherus BioSciences VEGF Inhibitors Sales by Product in 2024
11.3.6 Coherus BioSciences VEGF Inhibitors Sales by Application in 2024
11.3.7 Coherus BioSciences VEGF Inhibitors Sales by Geographic Area in 2024
11.3.8 Coherus BioSciences VEGF Inhibitors SWOT Analysis
11.3.9 Coherus BioSciences Recent Developments
11.4 Bayer
11.4.1 Bayer Corporation Information
11.4.2 Bayer Business Overview
11.4.3 Bayer VEGF Inhibitors Product Models, Descriptions and Specifications
11.4.4 Bayer VEGF Inhibitors Sales, Price, Revenue and Gross Margin (2020-2025)
11.4.5 Bayer VEGF Inhibitors Sales by Product in 2024
11.4.6 Bayer VEGF Inhibitors Sales by Application in 2024
11.4.7 Bayer VEGF Inhibitors Sales by Geographic Area in 2024
11.4.8 Bayer VEGF Inhibitors SWOT Analysis
11.4.9 Bayer Recent Developments
11.5 Amneal Pharmaceuticals
11.5.1 Amneal Pharmaceuticals Corporation Information
11.5.2 Amneal Pharmaceuticals Business Overview
11.5.3 Amneal Pharmaceuticals VEGF Inhibitors Product Models, Descriptions and Specifications
11.5.4 Amneal Pharmaceuticals VEGF Inhibitors Sales, Price, Revenue and Gross Margin (2020-2025)
11.5.5 Amneal Pharmaceuticals VEGF Inhibitors Sales by Product in 2024
11.5.6 Amneal Pharmaceuticals VEGF Inhibitors Sales by Application in 2024
11.5.7 Amneal Pharmaceuticals VEGF Inhibitors Sales by Geographic Area in 2024
11.5.8 Amneal Pharmaceuticals VEGF Inhibitors SWOT Analysis
11.5.9 Amneal Pharmaceuticals Recent Developments
11.6 Sanofi
11.6.1 Sanofi Corporation Information
11.6.2 Sanofi Business Overview
11.6.3 Sanofi VEGF Inhibitors Product Models, Descriptions and Specifications
11.6.4 Sanofi VEGF Inhibitors Sales, Price, Revenue and Gross Margin (2020-2025)
11.6.5 Sanofi Recent Developments
11.7 Samsung Bioepis
11.7.1 Samsung Bioepis Corporation Information
11.7.2 Samsung Bioepis Business Overview
11.7.3 Samsung Bioepis VEGF Inhibitors Product Models, Descriptions and Specifications
11.7.4 Samsung Bioepis VEGF Inhibitors Sales, Price, Revenue and Gross Margin (2020-2025)
11.7.5 Samsung Bioepis Recent Developments
11.8 Eli Lilly
11.8.1 Eli Lilly Corporation Information
11.8.2 Eli Lilly Business Overview
11.8.3 Eli Lilly VEGF Inhibitors Product Models, Descriptions and Specifications
11.8.4 Eli Lilly VEGF Inhibitors Sales, Price, Revenue and Gross Margin (2020-2025)
11.8.5 Eli Lilly Recent Developments
11.9 Pfizer
11.9.1 Pfizer Corporation Information
11.9.2 Pfizer Business Overview
11.9.3 Pfizer VEGF Inhibitors Product Models, Descriptions and Specifications
11.9.4 Pfizer VEGF Inhibitors Sales, Price, Revenue and Gross Margin (2020-2025)
11.9.5 Pfizer Recent Developments
11.10 Celltrion Healthcare
11.10.1 Celltrion Healthcare Corporation Information
11.10.2 Celltrion Healthcare Business Overview
11.10.3 Celltrion Healthcare VEGF Inhibitors Product Models, Descriptions and Specifications
11.10.4 Celltrion Healthcare VEGF Inhibitors Sales, Price, Revenue and Gross Margin (2020-2025)
11.10.5 Celltrion Healthcare Recent Developments
11.11 Amgen
11.11.1 Amgen Corporation Information
11.11.2 Amgen Business Overview
11.11.3 Amgen VEGF Inhibitors Product Models, Descriptions and Specifications
11.11.4 Amgen VEGF Inhibitors Sales, Price, Revenue and Gross Margin (2020-2025)
11.11.5 Amgen Recent Developments
11.12 Chengdu Kanghong Pharmaceutical
11.12.1 Chengdu Kanghong Pharmaceutical Corporation Information
11.12.2 Chengdu Kanghong Pharmaceutical Business Overview
11.12.3 Chengdu Kanghong Pharmaceutical VEGF Inhibitors Product Models, Descriptions and Specifications
11.12.4 Chengdu Kanghong Pharmaceutical VEGF Inhibitors Sales, Price, Revenue and Gross Margin (2020-2025)
11.12.5 Chengdu Kanghong Pharmaceutical Recent Developments
12 Value Chain and Supply-Chain Analysis
12.1 VEGF Inhibitors Industry Chain
12.2 VEGF Inhibitors Upstream Materials Analysis
12.2.1 Raw Materials
12.2.2 Key Suppliers Market Share & Risk Assessment
12.3 VEGF Inhibitors Integrated Production Analysis
12.3.1 Manufacturing Footprint Analysis
12.3.2 Regional Production Market Share (2020-2031)
12.3.3 Regulatory and Trade Policy Impact on Production
12.3.4 Production Technology Overview
12.3.5 Regional Cost Drivers
12.4 VEGF Inhibitors Sales Channels and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors
13 VEGF Inhibitors Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
14 Key Findings in the Global VEGF Inhibitors Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details
List of Tables
Table 1. Global VEGF Inhibitors Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Table 2. Global VEGF Inhibitors Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Table 3. Global VEGF Inhibitors Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 4. Global VEGF Inhibitors Revenue by Region (2020-2025) & (US$ Million)
Table 5. Global VEGF Inhibitors Revenue by Region (2026-2031) & (US$ Million)
Table 6. Global VEGF Inhibitors Sales Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (K Units)
Table 7. Global VEGF Inhibitors Sales by Region (2020-2025) & (K Units)
Table 8. Global VEGF Inhibitors Sales by Region (2026-2031) & (K Units)
Table 9. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 10. Global VEGF Inhibitors Sales by Manufacturers (2020-2025) & (K Units)
Table 11. Global VEGF Inhibitors Sales Share by Manufacturers (2020-2025)
Table 12. Global VEGF Inhibitors Revenue by Manufacturers (2020-2025) & (US$ Million)
Table 13. Global VEGF Inhibitors Revenue Market Share by Manufacturers (2020-2025)
Table 14. Global Key Manufacturers’Ranking Shift (2023 vs. 2024) (Based on Revenue)
Table 15. Global VEGF Inhibitors by Manufacturer Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in VEGF Inhibitors as of 2024)
Table 16. Global VEGF Inhibitors Average Gross Margin (%) by Manufacturer (2020 VS 2024)
Table 17. Global VEGF Inhibitors Average Selling Price (ASP) by Manufacturers (2020-2025) & (US$/Unit)
Table 18. Key Manufacturers VEGF Inhibitors Manufacturing Base and Headquarters
Table 19. Global VEGF Inhibitors Market Concentration Ratio (CR5 and HHI)
Table 20. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
Table 21. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 22. Global VEGF Inhibitors Sales by Type (2020-2025) & (K Units)
Table 23. Global VEGF Inhibitors Sales by Type (2026-2031) & (K Units)
Table 24. Global VEGF Inhibitors Revenue by Type (2020-2025) & (US$ Million)
Table 25. Global VEGF Inhibitors Revenue by Type (2026-2031) & (US$ Million)
Table 26. Global VEGF Inhibitors ASP by Type (2020-2031) & (US$/Unit)
Table 27. Technical Specifications by Key Product Type
Table 28. Global VEGF Inhibitors Sales by Application (2020-2025) & (K Units)
Table 29. Global VEGF Inhibitors Sales by Application (2026-2031) & (K Units)
Table 30. VEGF Inhibitors High-Growth Sectors Demand CAGR (2024-2031)
Table 31. Global VEGF Inhibitors Revenue by Application (2020-2025) & (US$ Million)
Table 32. Global VEGF Inhibitors Revenue by Application (2026-2031) & (US$ Million)
Table 33. Global VEGF Inhibitors ASP by Application (2020-2031) & (US$/Unit)
Table 34. Top Customers by Region
Table 35. Top Customers by Application
Table 36. North America VEGF Inhibitors Growth Accelerators and Market Barriers
Table 37. North America VEGF Inhibitors Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 38. North America VEGF Inhibitors Sales (K Units) by Country (2020 VS 2024 VS 2031)
Table 39. Europe VEGF Inhibitors Growth Accelerators and Market Barriers
Table 40. Europe VEGF Inhibitors Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 41. Europe VEGF Inhibitors Sales (K Units) by Country (2020 VS 2024 VS 2031)
Table 42. Asia-Pacific VEGF Inhibitors Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 43. Asia-Pacific VEGF Inhibitors Sales (K Units) by Country (2020 VS 2024 VS 2031)
Table 44. Asia-Pacific VEGF Inhibitors Growth Accelerators and Market Barriers
Table 45. Southeast Asia VEGF Inhibitors Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 46. Central and South America VEGF Inhibitors Investment Opportunities and Key Challenges
Table 47. Central and South America VEGF Inhibitors Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 48. Middle East and Africa VEGF Inhibitors Investment Opportunities and Key Challenges
Table 49. Middle East and Africa VEGF Inhibitors Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 50. Roche Corporation Information
Table 51. Roche Description and Major Businesses
Table 52. Roche Product Models, Descriptions and Specifications
Table 53. Roche Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 54. Roche Sales Value Proportion by Product in 2024
Table 55. Roche Sales Value Proportion by Application in 2024
Table 56. Roche Sales Value Proportion by Geographic Area in 2024
Table 57. Roche VEGF Inhibitors SWOT Analysis
Table 58. Roche Recent Developments
Table 59. Novartis Corporation Information
Table 60. Novartis Description and Major Businesses
Table 61. Novartis Product Models, Descriptions and Specifications
Table 62. Novartis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 63. Novartis Sales Value Proportion by Product in 2024
Table 64. Novartis Sales Value Proportion by Application in 2024
Table 65. Novartis Sales Value Proportion by Geographic Area in 2024
Table 66. Novartis VEGF Inhibitors SWOT Analysis
Table 67. Novartis Recent Developments
Table 68. Coherus BioSciences Corporation Information
Table 69. Coherus BioSciences Description and Major Businesses
Table 70. Coherus BioSciences Product Models, Descriptions and Specifications
Table 71. Coherus BioSciences Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 72. Coherus BioSciences Sales Value Proportion by Product in 2024
Table 73. Coherus BioSciences Sales Value Proportion by Application in 2024
Table 74. Coherus BioSciences Sales Value Proportion by Geographic Area in 2024
Table 75. Coherus BioSciences VEGF Inhibitors SWOT Analysis
Table 76. Coherus BioSciences Recent Developments
Table 77. Bayer Corporation Information
Table 78. Bayer Description and Major Businesses
Table 79. Bayer Product Models, Descriptions and Specifications
Table 80. Bayer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 81. Bayer Sales Value Proportion by Product in 2024
Table 82. Bayer Sales Value Proportion by Application in 2024
Table 83. Bayer Sales Value Proportion by Geographic Area in 2024
Table 84. Bayer VEGF Inhibitors SWOT Analysis
Table 85. Bayer Recent Developments
Table 86. Amneal Pharmaceuticals Corporation Information
Table 87. Amneal Pharmaceuticals Description and Major Businesses
Table 88. Amneal Pharmaceuticals Product Models, Descriptions and Specifications
Table 89. Amneal Pharmaceuticals Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 90. Amneal Pharmaceuticals Sales Value Proportion by Product in 2024
Table 91. Amneal Pharmaceuticals Sales Value Proportion by Application in 2024
Table 92. Amneal Pharmaceuticals Sales Value Proportion by Geographic Area in 2024
Table 93. Amneal Pharmaceuticals VEGF Inhibitors SWOT Analysis
Table 94. Amneal Pharmaceuticals Recent Developments
Table 95. Sanofi Corporation Information
Table 96. Sanofi Description and Major Businesses
Table 97. Sanofi Product Models, Descriptions and Specifications
Table 98. Sanofi Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 99. Sanofi Recent Developments
Table 100. Samsung Bioepis Corporation Information
Table 101. Samsung Bioepis Description and Major Businesses
Table 102. Samsung Bioepis Product Models, Descriptions and Specifications
Table 103. Samsung Bioepis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 104. Samsung Bioepis Recent Developments
Table 105. Eli Lilly Corporation Information
Table 106. Eli Lilly Description and Major Businesses
Table 107. Eli Lilly Product Models, Descriptions and Specifications
Table 108. Eli Lilly Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 109. Eli Lilly Recent Developments
Table 110. Pfizer Corporation Information
Table 111. Pfizer Description and Major Businesses
Table 112. Pfizer Product Models, Descriptions and Specifications
Table 113. Pfizer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 114. Pfizer Recent Developments
Table 115. Celltrion Healthcare Corporation Information
Table 116. Celltrion Healthcare Description and Major Businesses
Table 117. Celltrion Healthcare Product Models, Descriptions and Specifications
Table 118. Celltrion Healthcare Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 119. Celltrion Healthcare Recent Developments
Table 120. Amgen Corporation Information
Table 121. Amgen Description and Major Businesses
Table 122. Amgen Product Models, Descriptions and Specifications
Table 123. Amgen Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 124. Amgen Recent Developments
Table 125. Chengdu Kanghong Pharmaceutical Corporation Information
Table 126. Chengdu Kanghong Pharmaceutical Description and Major Businesses
Table 127. Chengdu Kanghong Pharmaceutical Product Models, Descriptions and Specifications
Table 128. Chengdu Kanghong Pharmaceutical Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 129. Chengdu Kanghong Pharmaceutical Recent Developments
Table 130. Key Raw Materials Distribution
Table 131. Raw Materials Key Suppliers
Table 132. Critical Raw Material Supplier Concentration (2024) & Risk Index
Table 133. Milestones in Production Technology Evolution
Table 134. Distributors List
Table 135. Market Trends and Market Evolution
Table 136. Market Drivers and Opportunities
Table 137. Market Challenges, Risks, and Restraints
Table 138. Research Programs/Design for This Report
Table 139. Key Data Information from Secondary Sources
Table 140. Key Data Information from Primary Sources


List of Figures
Figure 1. VEGF Inhibitors Product Picture
Figure 2. Global VEGF Inhibitors Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Figure 3. Monoclonal Antibodies Product Picture
Figure 4. Fusion Proteins Product Picture
Figure 5. Global VEGF Inhibitors Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Figure 6. Degenerative Eye Diseases
Figure 7. Cancer
Figure 8. Other
Figure 9. VEGF Inhibitors Report Years Considered
Figure 10. Global VEGF Inhibitors Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 11. Global VEGF Inhibitors Revenue (2020-2031) & (US$ Million)
Figure 12. Global VEGF Inhibitors Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Figure 13. Global VEGF Inhibitors Revenue Market Share by Region (2020-2031)
Figure 14. Global VEGF Inhibitors Sales (2020-2031) & (K Units)
Figure 15. Global VEGF Inhibitors Sales (CAGR) by Region (2020-2031) (K Units)
Figure 16. Global VEGF Inhibitors Sales Market Share by Region (2020-2031)
Figure 17. Top 5 and Top 10 Manufacturers VEGF Inhibitors Sales Volume Market Share in 2024
Figure 18. Global VEGF Inhibitors Revenue Market Share Ranking (2024)
Figure 19. Tier Distribution by Revenue Contribution (2020 VS 2024)
Figure 20. Monoclonal Antibodies Revenue Market Share by Manufacturer in 2024
Figure 21. Fusion Proteins Revenue Market Share by Manufacturer in 2024
Figure 22. Global VEGF Inhibitors Sales Market Share by Type (2020-2031)
Figure 23. Global VEGF Inhibitors Revenue Market Share by Type (2020-2031)
Figure 24. Global VEGF Inhibitors Sales Market Share by Application (2020-2031)
Figure 25. Global VEGF Inhibitors Revenue Market Share by Application (2020-2031)
Figure 26. North America VEGF Inhibitors Sales YoY (2020-2031) & (K Units)
Figure 27. North America VEGF Inhibitors Revenue YoY (2020-2031) & (US$ Million)
Figure 28. North America Top 5 Manufacturers VEGF Inhibitors Sales Revenue (US$ Million) in 2024
Figure 29. North America VEGF Inhibitors Sales Volume (K Units) by Type (2020- 2031)
Figure 30. North America VEGF Inhibitors Sales Revenue (US$ Million) by Type (2020 - 2031)
Figure 31. North America VEGF Inhibitors Sales Volume (K Units) by Application (2020-2031)
Figure 32. North America VEGF Inhibitors Sales Revenue (US$ Million) by Application (2020-2031)
Figure 33. US VEGF Inhibitors Revenue (2020-2031) & (US$ Million)
Figure 34. Canada VEGF Inhibitors Revenue (2020-2031) & (US$ Million)
Figure 35. Mexico VEGF Inhibitors Revenue (2020-2031) & (US$ Million)
Figure 36. Europe VEGF Inhibitors Sales YoY (2020-2031) & (K Units)
Figure 37. Europe VEGF Inhibitors Revenue YoY (2020-2031) & (US$ Million)
Figure 38. Europe Top 5 Manufacturers VEGF Inhibitors Sales Revenue (US$ Million) in 2024
Figure 39. Europe VEGF Inhibitors Sales Volume (K Units) by Type (2020-2031)
Figure 40. Europe VEGF Inhibitors Sales Revenue (US$ Million) by Type (2020-2031)
Figure 41. Europe VEGF Inhibitors Sales Volume (K Units) by Application (2020-2031)
Figure 42. Europe VEGF Inhibitors Sales Revenue (US$ Million) by Application (2020-2031)
Figure 43. Germany VEGF Inhibitors Revenue (2020-2031) & (US$ Million)
Figure 44. France VEGF Inhibitors Revenue (2020-2031) & (US$ Million)
Figure 45. U.K. VEGF Inhibitors Revenue (2020-2031) & (US$ Million)
Figure 46. Italy VEGF Inhibitors Revenue (2020-2031) & (US$ Million)
Figure 47. Russia VEGF Inhibitors Revenue (2020-2031) & (US$ Million)
Figure 48. Asia-Pacific VEGF Inhibitors Sales YoY (2020-2031) & (K Units)
Figure 49. Asia-Pacific VEGF Inhibitors Revenue YoY (2020-2031) & (US$ Million)
Figure 50. Asia-Pacific Top 8 Manufacturers VEGF Inhibitors Sales Revenue (US$ Million) in 2024
Figure 51. Asia-Pacific VEGF Inhibitors Sales Volume (K Units) by Type (2020- 2031)
Figure 52. Asia-Pacific VEGF Inhibitors Sales Revenue (US$ Million) by Type (2020- 2031)
Figure 53. Asia-Pacific VEGF Inhibitors Sales Volume (K Units) by Application (2020-2031)
Figure 54. Asia-Pacific VEGF Inhibitors Sales Revenue (US$ Million) by Application (2020-2031)
Figure 55. Indonesia VEGF Inhibitors Revenue (2020-2031) & (US$ Million)
Figure 56. Japan VEGF Inhibitors Revenue (2020-2031) & (US$ Million)
Figure 57. South Korea VEGF Inhibitors Revenue (2020-2031) & (US$ Million)
Figure 58. China Taiwan VEGF Inhibitors Revenue (2020-2031) & (US$ Million)
Figure 59. India VEGF Inhibitors Revenue (2020-2031) & (US$ Million)
Figure 60. Central and South America VEGF Inhibitors Sales YoY (2020-2031) & (K Units)
Figure 61. Central and South America VEGF Inhibitors Revenue YoY (2020-2031) & (US$ Million)
Figure 62. Central and South America Top 5 Manufacturers VEGF Inhibitors Sales Revenue (US$ Million) in 2024
Figure 63. Central and South America VEGF Inhibitors Sales Volume (K Units) by Type (2021-2031)
Figure 64. Central and South America VEGF Inhibitors Sales Revenue (US$ Million) by Type (2020-2031)
Figure 65. Central and South America VEGF Inhibitors Sales Volume (K Units) by Application (2020-2031)
Figure 66. Central and South America VEGF Inhibitors Sales Revenue (US$ Million) by Application (2020-2031)
Figure 67. Brazil VEGF Inhibitors Revenue (2020-2025) & (US$ Million)
Figure 68. Argentina VEGF Inhibitors Revenue (2020-2025) & (US$ Million)
Figure 69. Middle East, and Africa VEGF Inhibitors Sales YoY (2020-2031) & (K Units)
Figure 70. Middle East and Africa VEGF Inhibitors Revenue YoY (2020-2031) & (US$ Million)
Figure 71. Middle East and Africa Top 5 Manufacturers VEGF Inhibitors Sales Revenue (US$ Million) in 2024
Figure 72. Middle East and Africa VEGF Inhibitors Sales Volume (K Units) by Type (2021-2031)
Figure 73. South America VEGF Inhibitors Sales Revenue (US$ Million) by Type (2020-2031)
Figure 74. Middle East and Africa VEGF Inhibitors Sales Volume (K Units) by Application (2020-2031)
Figure 75. Middle East and Africa VEGF Inhibitors Sales Revenue (US$ Million) by Application (2020-2031)
Figure 76. GCC Countries VEGF Inhibitors Revenue (2020-2025) & (US$ Million)
Figure 77. Turkey VEGF Inhibitors Revenue (2020-2025) & (US$ Million)
Figure 78. Egypt VEGF Inhibitors Revenue (2020-2025) & (US$ Million)
Figure 79. South Africa VEGF Inhibitors Revenue (2020-2025) & (US$ Million)
Figure 80. VEGF Inhibitors Industry Chain Mapping
Figure 81. Regional VEGF Inhibitors Manufacturing Base Distribution (%)
Figure 82. Global VEGF Inhibitors Production Market Share by Region (2020-2031)
Figure 83. VEGF Inhibitors Production Process
Figure 84. Regional VEGF Inhibitors Production Cost Structure
Figure 85. Channels of Distribution (Direct Vs Distribution)
Figure 86. Bottom-up and Top-down Approaches for This Report
Figure 87. Data Triangulation
Figure 88. Key Executives Interviewed
Choose Your Edition
Add to cart

Our team would be happy to assist you with your queries.

Contact us

About us

Accurate data, The latest market trends, And deeper research directions.

Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals

Latest reports

Useful links

Our Contacts

Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China

(+86) 159 1069 5232

sales@hengceresearch.com
hengceresearch.com

Allow cookies